Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Dean Gaalaas, Karl Odquist

Premium

Dean Gaalaas has joined GeneDx as COO. Gaalaas was previously CEO of Edge Biosystems, but made the move to GeneDx as part of an acquisition by GeneDx's parent company BioReference Laboratories of EdgeBio's sequencing services business, Edge BioServ. Gaalaas joined EdgeBio in 1999, becoming its CEO in 2004.


Pathway Genomics has named Karl Odquist as executive director of managed care. He will be responsible for managed care contracting, reimbursement, government affairs, and clinical evidence generation for the company’s diagnostic services.

Odquist has served in various roles at pharmaceutical and diagnostic companies, most recently at Prometheus Laboratories.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.